found that PDGFRB co-expressed with EGRF, exerted a combinatorial effect to induce resistance to EGFR-targeted therapy, and increased the tumorigenicity and invasiveness of bladder tumors (45). Here, PDGFRB is linked to urinary bladder neoplasm.